

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Ranatunge et al**

Application No: **10/608,333**

Group Art Unit: **1626**

Filed: **June 30, 2003**

Examiner: **T.A. Solola**

For: **Oxime and/or Hydrazone containing Nitrosated and/or Nitrosylated Cyclooxygenase-2 Inhibitors, Compositions and Methods of Uses**

Attorney Docket No: **102258.153 US1**

Commissioner of Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C. F. R. §§1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 Form.


Applicants are providing a copy of all the cited references except for the US patents.

The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

This Information Disclosure Statement is being filed after the mailing date of a first office action on the merits and before a notice of allowance. Accordingly, the Commissioner is authorized to charge the fee of \$180.00 to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted

By 
Belinda M. Lew
Registration No.: 53,212

Date: JANUARY 19, 2006

WILMER CUTLER PICKERING HALE AND

DORR LLP

The Willard Office Building

1455 Pennsylvania Avenue, NW

Washington, DC 20004

(202) 942-84400

| | | | | | | | |
|---|------------|------------|--------------|------------------------------|----------|----------------|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) | | | | ATTY. DOCKET NO. | | SERIAL NO. | |
| | | | | 102258.153 US1 | | 10/608,333 | |
| | | | | | | | |
| | | | | APPLICANT Ranatunge et al | | | |
| | | | | FILING DATE June 30, 2003 | | GROUP 1626 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER'S INITIALS | PATENT NO. | ISSUE DATE | NAME | CLASS | SUBCLASS | FILING DATE | |
| | 5,134,142 | 07/28/1992 | Matsuo et al | | | | |
| | 5,466,823 | 11/14/1995 | Talley et al | | | | |
| | 5,504,215 | 04/2/1996 | Talley et al | | | | |
| | 5,508,426 | 04/16/1996 | Talley et al | | | | |
| | 5,510,496 | 04/23/1996 | Talley et al | | | | |
| | 5,516,907 | 05/14/1996 | Talley et al | | | | |
| | 5,521,207 | 05/28/1996 | Graneto | | | | |
| | 5,550,147 | 08/27/1996 | Matsuo et al | | | | |
| | 5,580,985 | 12/03/1996 | Lee et al | | | | |
| | 5,670,533 | 09/23/1997 | Matsuo et al | | | | |
| | 5,753,688 | 05/19/1998 | Talley et al | | | | |
| | 5,760,068 | 06/02/1998 | Talley et al | | | | |
| | 6,083,969 | 07/04/2000 | Ferro et al | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) | | | | ATTY. DOCKET NO. | | SERIAL NO. | |
|---|----------------|------------|---------|------------------------------|----------|-------------|----|
| | | | | 102258.153 US1 | | 10/608,333 | |
| | | | | | | | |
| | | | | APPLICANT Ranatunge et al | | | |
| FILING DATE June 30, 2003 | | | | GROUP 1626 | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| EXAMINER'S INITIALS | PATENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | Translation | |
| | | | | | | Yes | No |
| | 95/15315 | 06/08/1995 | WIPO | | | | |
| | 95/15317 | 06/08/1995 | WIPO | | | | |
| | 95/15318 | 06/08/1995 | WIPO | | | | |
| | 96/03388 | 02/08/1996 | WIPO | | | | |
| | 96/09293 | 03/28/1996 | WIPO | | | | |
| | 97/11704 | 04/03/1997 | WIPO | | | | |
| | 97/13755 | 04/17/1997 | WIPO | | | | |
| | 97/27181 | 07/31/1997 | WIPO | | | | |
| | 98/11080 | 03/19/1998 | WIPO | | | | |
| | 98/22442 | 05/28/1998 | WIPO | | | | |
| | 98/46594 | 10/11/1998 | WIPO | | | | |
| | 99/64415 | 12/16/1999 | WIPO | | | | |
| | 2000/066562 | 11/09/2000 | WIPO | | | | |
| | 2004/043934 A1 | 05/27/2004 | WIPO | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449) | | | | ATTY. DOCKET NO. | | SERIAL NO. | |
|---|--|------------|---------|------------------------------|----------|---------------|----|
| | | | | 102258.153 US1 | | 10/608,333 | |
| | | | | APPLICANT Ranatunge et al | | | |
| | | | | FILING DATE June 30, 2003 | | GROUP 1626 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| EXAMINER'S INITIALS | PATENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | Translation | |
| | | | | | | Yes | No |
| | 0 418 845 B1 | 08/09/1995 | EP | | | | |
| | 0 554 829 A2 | 08/11/1993 | EP | | | | |
| | 1 006 114 A1 | 06/7/2000 | EP | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | Desiraju et al; <i>Molecules.</i> ; 5(7): 945-955 (2000) | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.